A PALB2 genetic test looks for an inherited variant in a gene that works with BRCA1 and BRCA2 to repair broken DNA. A pathogenic germline PALB2 variant substantially raises female breast cancer risk and also increases the risks of pancreatic cancer, male breast cancer, and, to a smaller degree, ovarian cancer. The test usually uses blood or saliva and is often included in a hereditary breast, ovarian, and pancreatic cancer panel.
A positive result does not mean cancer is present or inevitable. It can change breast screening, support discussion of risk-reducing surgery, affect pancreatic surveillance eligibility, and provide a clear test for relatives. A negative result is most informative when the person is tested for a known family variant. A variant of uncertain significance, or VUS, does not establish inherited cancer risk and should not be used by itself to choose preventive surgery. Tumor-only PALB2 findings also require careful review because they may be acquired changes limited to cancer cells rather than inherited variants.
- A pathogenic or likely pathogenic PALB2 variant can explain hereditary breast and pancreatic cancer susceptibility.
- Female breast cancer risk is often estimated near 35% to 55% or higher, depending on family history and the study used.
- Annual breast MRI and mammography commonly begin around age 30 for adult female carriers.
- Each child, sibling, or parent of a carrier may have a 50% chance of carrying the same variant.
- A VUS is not a positive result and should not guide mastectomy, ovary removal, or family predictive testing.
- Two pathogenic PALB2 variants can cause a rare form of Fanconi anemia in children.
Table of Contents
- What the PALB2 Gene Does
- Who May Need PALB2 Testing
- How PALB2 Testing Is Performed
- Understanding PALB2 Results
- Breast, Pancreatic, and Ovarian Cancer Risks
- Screening and Risk Reduction
- PALB2 and Cancer Treatment
- Family Testing, Reproduction, and Next Steps
What the PALB2 Gene Does
PALB2 stands for “partner and localizer of BRCA2.” The PALB2 protein helps position BRCA2 at sites where both strands of DNA have broken. Together with BRCA1, BRCA2, RAD51, and other proteins, it supports homologous recombination, a high-accuracy repair process that uses an intact DNA copy as a template.
When one inherited PALB2 copy is not working, cells still have a second functional copy. Cancer risk rises when a breast, pancreatic, ovarian, or other cell later loses or disables that remaining copy. The cell then repairs double-strand breaks less accurately, allowing chromosome changes and mutations to accumulate.
PALB2 is therefore a tumor-suppressor gene. A pathogenic germline variant is present in most cells from birth, but it does not itself prove that a tumor exists. A somatic PALB2 variant develops in a particular tissue or tumor and may not be inherited. The distinction matters for relatives, prevention, and sometimes treatment.
PALB2-related cancer susceptibility follows autosomal dominant inheritance. Each child of a carrier has a 50% chance of inheriting the variant. Brothers and sisters may also have a 50% chance if one parent carried it. Men and women can inherit and pass on PALB2 even though their cancer patterns differ.
A child who inherits a pathogenic PALB2 variant from both parents can develop Fanconi anemia type N. This rare autosomal recessive condition can cause congenital abnormalities, bone marrow failure, and childhood cancers. The possibility is especially important when both partners have a personal or family history suggestive of PALB2 or when one partner is already known to carry a variant.
PALB2 overlaps biologically with BRCA1 and BRCA2, but risk estimates, approved therapies, and prevention guidance are not identical. A PALB2 result should be managed using PALB2-specific evidence rather than automatically copied from BRCA guidance.
Who May Need PALB2 Testing
PALB2 testing is usually offered as part of a multigene panel when personal or family history suggests hereditary breast, ovarian, pancreatic, or male breast cancer. Modern breast cancer testing recommendations have broadened, so many patients qualify even without a striking family history.
Common reasons include:
- breast cancer at a young age;
- triple-negative breast cancer or bilateral breast cancer;
- male breast cancer;
- breast cancer plus pancreatic or ovarian cancer in the same family;
- pancreatic cancer at any age in many current testing pathways;
- multiple relatives with breast cancer on the same side of the family;
- a known PALB2 pathogenic variant in a relative;
- Ashkenazi Jewish or another ancestry with a relevant founder variant, together with personal or family history;
- tumor sequencing that identifies a PALB2 variant that could be germline; or
- previous negative BRCA1/BRCA2 testing that did not include PALB2 or other genes.
Testing is also reasonable for some people with limited family information. Adoption, small families, few female relatives, early deaths, and family estrangement can hide a hereditary pattern. Paternal family history is as important as maternal history because PALB2 can be transmitted through either parent.
When possible, testing starts with a relative who has had cancer. An affected person is more likely to reveal the inherited cause. If that person has a pathogenic PALB2 variant, unaffected relatives can receive a focused familial-variant test with a clear positive or true-negative interpretation.
A hereditary cancer genetic panel often includes PALB2 with BRCA1, BRCA2, ATM, CHEK2, TP53, PTEN, CDH1, and other genes. Panels are useful because the same family history can result from several syndromes. They also increase the chance of a VUS or an unexpected pathogenic result, so pretest counseling should address the possible range of findings.
Testing may be ordered rapidly after a new cancer diagnosis when the result could affect surgery or systemic therapy. A newly diagnosed patient should understand that receiving a result quickly does not require an immediate preventive decision. Treatment of the known cancer and management of future inherited risk are related but separate choices.
How PALB2 Testing Is Performed
Germline testing usually uses a blood sample, saliva, or a cheek swab. No fasting is required. The laboratory sequences PALB2 and checks for larger deletions or duplications. Full analysis is important because pathogenic variants occur throughout the gene; testing only one founder variant is not complete for most people.
Next-generation sequencing reads many gene regions at once. Sanger sequencing may confirm a finding or test a relative for the exact family variant. Copy-number analysis identifies exon-level or whole-gene deletions and duplications that standard sequence analysis can miss.
The laboratory classifies each variant as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign. Pathogenic and likely pathogenic variants are generally considered actionable. Benign and likely benign findings do not explain hereditary PALB2 risk. A VUS remains unresolved.
The report should specify the DNA and protein notation, zygosity, classification, evidence used, and methods. Most adult hereditary cancer results are heterozygous, meaning one PALB2 copy carries the variant. Two pathogenic variants require prompt specialist review because of possible Fanconi anemia implications and because phase—whether the variants are on opposite gene copies—must be clarified.
Tumor sequencing creates a common source of confusion. A PALB2 variant in a breast or pancreatic tumor may be inherited, may be acquired only in the tumor, or may reflect both. The variant allele fraction cannot settle this by itself. Confirmation requires a germline sample and appropriate consent. Conversely, a germline test does not show whether the tumor has lost the remaining working PALB2 copy.
Blood is usually reliable, but special sampling may be needed after an allogeneic stem-cell transplant because donor cells can replace the patient’s blood DNA. Active hematologic cancer can also introduce acquired variants. Cultured skin fibroblasts or another nonblood tissue may be recommended in those circumstances.
Results often return within two to several weeks. Before testing, counseling should cover medical management, family communication, privacy and insurance limits, reproductive issues, possible secondary findings, and the emotional effect of an uncertain or positive result.
Understanding PALB2 Results
The same word—negative, positive, or uncertain—can carry different meaning depending on family context.
| Result | Usual meaning | Typical action |
|---|---|---|
| Pathogenic or likely pathogenic | An inherited PALB2 change is expected to impair gene function and raise cancer risk. | Use PALB2-specific screening, discuss prevention, and offer family testing. |
| Negative for a known family variant | The person did not inherit the documented familial PALB2 cause. | Usually follow screening based on personal history and other family factors. |
| Negative without a known family variant | No reportable PALB2 cause was found, but hereditary risk may remain unexplained. | Review whether a broader panel, another affected relative, or updated testing is appropriate. |
| Variant of uncertain significance | Evidence is insufficient to call the change harmful or harmless. | Do not use the VUS alone for surgery, intensified screening, or predictive testing. |
| Somatic PALB2 variant | The change was found in a tumor and may not be present in the germline. | Consider confirmatory germline testing and separate treatment interpretation. |
A positive result indicates susceptibility, not certainty. Some carriers never develop cancer. Risk also changes with age; a 25-year-old and a 70-year-old with the same variant do not have the same remaining lifetime risk. Family history, breast density, reproductive history, lifestyle, and other genetic factors can shift the estimate.
A true-negative result is the most reassuring negative. It occurs when the exact pathogenic variant is already documented in a family and the tested relative does not carry it. That person generally does not need PALB2-specific surveillance from that family branch, although personal history and the other side of the family still matter.
An uninformative negative does not erase a strong family history. The family may have a pathogenic variant in another gene, a PALB2 alteration the assay cannot detect, more than one cause, or a cluster of cancers without a single high-risk variant. Testing an affected relative can be more informative than expanding surveillance based only on a negative result in an unaffected person.
A VUS should remain medically neutral. Laboratories may later reclassify it as benign or, less often, pathogenic. Family members generally should not receive predictive testing for a VUS outside a structured genetics evaluation. Keep the report and ensure the ordering clinic has current contact information.
Breast, Pancreatic, and Ovarian Cancer Risks
Female breast cancer is the best-established PALB2-associated risk. Large family studies have estimated risk near 17% by age 50 and about 53% by age 80 on average, with higher estimates in families containing several young breast cancers. Other analyses produce somewhat lower or higher ranges. A practical counseling range is often approximately 35% to 55% or more over a lifetime.
PALB2-associated breast cancers can be estrogen receptor positive or negative. Triple-negative disease occurs more often than in unselected breast cancer, but not every PALB2 tumor is triple negative. Pathology alone cannot diagnose a germline variant.
After one breast cancer, risk of a new cancer in the opposite breast is elevated in some groups, especially premenopausal carriers and those whose first tumor was estrogen receptor negative. The decision between breast-conserving surgery, unilateral mastectomy, or bilateral mastectomy should include age, tumor features, radiation considerations, remaining breast risk, reconstruction, recovery, and personal values.
Male breast cancer remains uncommon in absolute terms, but PALB2 raises risk several-fold compared with the general male population. Men should report a new breast lump, nipple retraction, skin change, or discharge promptly.
Pancreatic cancer risk is also increased. Current estimates often fall around 5% to 10% over a lifetime, although confidence intervals are wide. Family history may identify carriers at particularly high risk and affects screening recommendations in some professional guidelines.
Ovarian cancer risk appears moderately increased but is much lower than the ovarian risk from BRCA1. Estimates are commonly around 3% to 5% by age 80. The evidence is less precise, so family history and age are important when discussing ovary and fallopian tube removal.
Associations with prostate, colorectal, gastric, and other cancers have been reported, but a clear independent PALB2 risk has not been established for all of them. Screening should not be expanded to every possible cancer without evidence or a family-specific reason.
Screening and Risk Reduction
For adult women with a pathogenic PALB2 variant, annual breast MRI with contrast and annual mammography commonly begin at age 30. Some clinics alternate them every six months so one imaging test occurs twice per year, while others perform both around the same time. Clinical breast examination and symptom awareness supplement imaging.
MRI is more sensitive than mammography in dense breasts but can produce false positives and requires contrast. Mammography remains useful for calcifications and other findings MRI may not show. Screening during pregnancy, lactation, kidney disease, or contrast allergy requires individualized planning.
Risk-reducing bilateral mastectomy can lower breast cancer risk substantially, but it has not been proven necessary for every PALB2 carrier. The choice depends on age, estimated risk, prior breast cancer, family history, ability to undergo MRI, body image, reconstructive preferences, surgical complications, and personal tolerance of uncertainty. Continued imaging is a valid option for many carriers.
Medication such as tamoxifen, raloxifene, or an aromatase inhibitor may lower estrogen receptor-positive breast cancer risk in appropriate women. PALB2-specific prevention data are limited, so clinicians use broader high-risk breast evidence and consider menopausal status, clot risk, bone health, uterus status, and side effects.
Risk-reducing salpingo-oophorectomy may be considered around age 45 to 50 after childbearing, particularly when ovarian cancer is present in the family. The benefit is less certain than for BRCA1. Premenopausal removal causes immediate menopause and can affect bone density, cardiovascular health, sexual function, and quality of life. Hormone therapy may be appropriate for some women without a personal contraindication.
Pancreatic surveillance generally uses MRI with magnetic resonance cholangiopancreatography, endoscopic ultrasound, or both. Many protocols begin at age 50 or ten years before the youngest pancreatic cancer in the family. Recommendations differ when there is no pancreatic family history, so screening should occur in an experienced high-risk program that can explain uncertain benefits, false positives, incidental cysts, and procedure risks.
Healthy weight, regular physical activity, limited alcohol, and avoiding tobacco support general cancer prevention but do not replace PALB2-specific screening. New breast, abdominal, back, digestive, or jaundice symptoms require diagnostic evaluation rather than a routine screening appointment.
PALB2 and Cancer Treatment
PALB2 loss can create homologous recombination deficiency, making tumor cells less able to repair double-strand DNA damage. This biology provides a rationale for platinum chemotherapy and PARP inhibitors, which exploit DNA-repair weakness.
Clinical studies have shown meaningful PARP inhibitor activity in some PALB2-mutated metastatic breast cancers. Platinum sensitivity has also been reported in breast and pancreatic cancers. However, treatment approvals and guideline recommendations vary by cancer type, drug, stage, and whether the PALB2 variant is germline or somatic. A result should not be interpreted as an automatic prescription.
For a person with breast cancer, PALB2 status may affect discussion of clinical trials, systemic treatment in advanced disease, and the risk of a second primary breast cancer. It does not automatically rule out breast-conserving surgery or radiation. The known tumor’s stage, receptor status, HER2 status, age, and general health remain central.
For pancreatic cancer, germline testing is important both for relatives and treatment planning. Platinum-containing regimens may be considered when clinically appropriate, and PALB2 carriers may qualify for DNA-repair–focused trials. PARP maintenance approvals that apply to BRCA-mutated pancreatic cancer should not be assumed to include PALB2 unless the current indication or trial specifically does so.
Tumor sequencing may show biallelic PALB2 loss, a homologous recombination signature, or only one uncertain alteration. These details affect how strongly the finding predicts drug sensitivity. Resistance can develop through restoration of the reading frame, alternate repair pathways, or other tumor evolution.
A germline result can also influence surgical timing, but urgent treatment should not be delayed unnecessarily. Decisions about removing the opposite healthy breast or ovaries can often be separated from immediate therapy for the diagnosed cancer.
Family Testing, Reproduction, and Next Steps
A pathogenic PALB2 result creates a direct cascade-testing path. Adult parents, siblings, and children each may have a 50% chance of carrying the familial variant. Testing more distant relatives proceeds through the side of the family from which the variant came.
Relatives should receive the actual laboratory report, not only the gene name. Targeted testing for the exact familial variant is faster and gives a clearer true-negative result than repeating a broad panel. A genetics clinic can provide a family letter that explains the finding without disclosing unnecessary personal details.
Testing children is usually deferred because adult PALB2 surveillance begins around age 30 and there is no routine childhood intervention for a single variant. Earlier testing may be considered only when results would change care or when biallelic Fanconi anemia is a concern.
If both reproductive partners carry pathogenic PALB2 variants, each pregnancy may have a 25% chance of Fanconi anemia type N, a 50% chance of a child carrying one variant, and a 25% chance of inheriting neither. Partner testing can be considered when one person is a carrier, particularly with consanguinity or a suggestive family history.
Reproductive options include natural conception, prenatal diagnosis, in vitro fertilization with preimplantation genetic testing, donor eggs or sperm, adoption, and choosing not to test. Counseling should be nondirective and explain test timing, limitations, cost, and the difference between adult cancer susceptibility and childhood Fanconi anemia.
After a positive result:
- Confirm that the variant is pathogenic or likely pathogenic and germline.
- Build a written breast screening schedule and discuss risk-reducing options.
- Review pancreatic screening criteria with a specialized program.
- Consider ovarian risk and timing of gynecologic prevention after childbearing.
- Tell the oncology team if cancer is present so treatment relevance can be assessed.
- Share the report with adult relatives and arrange targeted testing.
- Revisit recommendations as guidelines and family history change.
Seek prompt medical care for a new breast or underarm lump, nipple discharge, skin dimpling, jaundice, unexplained weight loss, persistent upper abdominal or back pain, or a new change in digestion. Screening is designed for people without symptoms; symptoms need diagnostic evaluation.
A PALB2 result is most useful when risk estimates are translated into a personal plan. The gene informs that plan, but age, family history, prior cancer, reproductive goals, and preferences determine how it is carried out.
References
- PALB2: Cancer Risks and Management (PDQ®) 2025 (Official Report)
- Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline 2024 (Guideline)
- Management of PALB2-associated breast cancer: A literature review and case report 2023 (Review)
- UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2 2023 (Guideline)
- Meta-Analysis of Breast Cancer Risk for Individuals with PALB2 Pathogenic Variants 2024 (Meta-Analysis)
- ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations 2022 (Guideline)
Disclaimer
PALB2 results estimate inherited cancer susceptibility and do not diagnose cancer or determine one mandatory surgery or drug. Decisions about MRI, mastectomy, ovary removal, pancreatic surveillance, and treatment should use the exact variant, age, family history, cancer history, and current specialist guidance. New breast changes, jaundice, or persistent abdominal symptoms need medical evaluation regardless of genetic status.
